Please login to the form below

Not currently logged in
Email:
Password:

AZ settles Seroquel patent case

AstraZeneca has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR in the US

AstraZeneca (AZ) has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR (quetiapine humarate) in the US.

AZ filed litigation against Accord following the company's submission to the US Food and Drug Administration (FDA) of an abbreviated new drug application for a generic version of the depression treatment.

As part of the agreement, AZ has granted Accord a licence to enter the US market with its generic Seroquel XR on November 1, 2016, or earlier, depending upon certain circumstances.

The drug is protected by patents and other exclusivity rights that range from March 2012 to November 2017.

Remaining Seroquel XR patent infringement litigations are ongoing.

6th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

World Mental Health Day 2019: Employment and Mental Illness
Mednet Group's white paper with a focus on navigating the world of work is available online in aid of World Mental Health Day 2019....
Changing direction
Changing direction: adapting to a rapidly-evolving environment
Chris Ross examines why creative partnerships could be key to commercial success in today’s healthcare marketplace...
customer journey
Understanding the patient journey
What we can learn from customer service...

Infographics